###begin article-title 0
###xml 28 33 <span type="species:ncbi:10090">Mouse</span>
CpG Island Methylation in a Mouse Model of Lymphoma Is Driven by the Genetic Configuration of Tumor Cells
###end article-title 0
###begin p 1
###xml 672 675 672 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 895 899 895 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 901 905 901 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53,</italic>
###xml 910 914 910 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 936 939 936 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 1470 1475 <span type="species:ncbi:9606">human</span>
Hypermethylation of CpG islands is a common epigenetic alteration associated with cancer. Global patterns of hypermethylation are tumor-type specific and nonrandom. The biological significance and the underlying mechanisms of tumor-specific aberrant promoter methylation remain unclear, but some evidence suggests that this specificity involves differential sequence susceptibilities, the targeting of DNA methylation activity to specific promoter sequences, or the selection of rare DNA methylation events during disease progression. Using restriction landmark genomic scanning on samples derived from tissue culture and in vivo models of T cell lymphomas, we found that MYC overexpression gave rise to a specific signature of CpG island hypermethylation. This signature reflected gene transcription profiles and was detected only in advanced stages of disease. The further inactivation of the Pten, p53, and E2f2 tumor suppressors in MYC-induced lymphomas resulted in distinct and diagnostic CpG island methylation signatures. Our data suggest that tumor-specific DNA methylation in lymphomas arises as a result of the selection of rare DNA methylation events during the course of tumor development. This selection appears to be driven by the genetic configuration of tumor cells, providing experimental evidence for a causal role of DNA hypermethylation in tumor progression and an explanation for the tremendous epigenetic heterogeneity observed in the evolution of human cancers. The ability to predict genome-wide epigenetic silencing based on relatively few genetic alterations will allow for a more complete classification of tumors and understanding of tumor cell biology.
###end p 1
###begin title 2
Author Summary
###end title 2
###begin title 3

###end title 3
###begin p 4
###xml 893 896 893 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 379 384 <span type="species:ncbi:9606">human</span>
###xml 612 617 <span type="species:ncbi:9606">human</span>
###xml 643 648 <span type="species:ncbi:10090">mouse</span>
###xml 853 857 <span type="species:ncbi:10090">mice</span>
###xml 1363 1368 <span type="species:ncbi:9606">human</span>
Genetic and epigenetic alterations of the genome are common features of cancers. The relationship between these two types of alterations, however, remains unclear. One type of epigenetic modification-DNA methylation in promoter sequences of genes-is of particular interest, since tumor cells have different patterns of promoter methylation than normal cells. Previous studies on human tumor samples have suggested a link between genetic alterations and the induction of aberrant DNA methylation; however, this link has been difficult to rigorously assess because of the incredible genetic heterogeneity found in human cancer. In this study, a mouse model of T cell lymphoma was used to explore the relationship between genetic and epigenetic modifications experienced by tumor cells. By introducing defined genetic changes into preneoplastic T cells of mice, such as the overexpression of the MYC oncogene and the ablation of tumor suppressor genes, we could carefully evaluate how these genetic changes impacted promoter methylation profiles during development of lymphomas in vivo. We found that the introduction of different genetic insults resulted in unique and diagnostic profiles of promoter methylation. Understanding how these methylation signatures contribute to tumor progression could eventually have diagnostic, prognostic, and therapeutic value for human cancers.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b001">1</xref>
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b002">2</xref>
###xml 612 613 612 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b003">3</xref>
###xml 833 838 833 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">INK4b</sup>
###xml 830 838 830 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p15<sup>INK4b</sup></italic>
###xml 843 848 843 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">INK4a</sup>
###xml 840 848 840 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p16<sup>INK4a</sup></italic>
###xml 850 855 850 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 857 860 857 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 865 869 865 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 871 872 871 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b003">3</xref>
###xml 873 874 873 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b004">4</xref>
###xml 1036 1037 1036 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b005">5</xref>
###xml 1038 1039 1038 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b006">6</xref>
###xml 1214 1215 1214 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b003">3</xref>
###xml 1216 1217 1216 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b007">7</xref>
###xml 1493 1494 1493 1494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b008">8</xref>
###xml 1495 1497 1495 1497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b010">10</xref>
###xml 1580 1582 1580 1582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b011">11</xref>
###xml 1583 1585 1583 1585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b013">13</xref>
###xml 1667 1669 1667 1669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b014">14</xref>
###xml 1670 1672 1670 1672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b015">15</xref>
###xml 257 262 <span type="species:ncbi:9606">human</span>
###xml 267 273 <span type="species:ncbi:10090">murine</span>
Tumor development is driven by complex patterns of genetic and epigenetic abnormalities. A causative role for genetic alterations in cancer has been established; however, the significance of what is perhaps the most common epigenetic change associated with human and murine malignancies, alterations in DNA methylation, is less clear [1]. DNA methylation changes include loss of DNA methylation (hypomethylation) in repetitive sequences, which is an event that has been linked to chromosomal instability, and gain of DNA methylation (hypermethylation) in CpG islands, which is associated with gene repression [2,3]. Convincing evidence for the significance of CpG island or promoter hypermethylation in tumor development stems from the observation that these events are associated with silencing of tumor suppressor genes such as p15INK4b, p16INK4a, BRCA1, VHL, or MLH1 [3,4]. More recent studies suggest that epigenetic mechanisms might even be involved in the expansion of premalignant cells during the early stages of tumorigenesis [5,6]. While CpG island methylation is associated with the silencing of a number of cancer-related genes, most CpG islands within the genome of the cancer cell remain unaffected [3,7]. The mechanisms involved in determining and maintaining the specificity of CpG island methylation during tumor development remain largely unknown, although several explanations for this phenomena have been provided, including differential susceptibilities of DNA sequences [8-10], the targeting of methyltransferase activity to specific promoters by oncogenes [11-13], and the selection for specific gene silencing events during tumor development [14,15].
###end p 6
###begin p 7
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b016">16</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b017">17</xref>
###xml 320 324 320 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 329 333 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 385 389 385 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b018">18</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b020">20</xref>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b021">21</xref>
###xml 776 778 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b022">22</xref>
###xml 631 636 <span type="species:ncbi:9606">human</span>
###xml 947 952 <span type="species:ncbi:10090">mouse</span>
Careful statistical analysis has led to contradicting results linking a relationship between genetic alterations and the epigenetic profile of cancer cells [16,17]. At least in colon cancer cells, defined sets of CpG island methylation events have been weakly associated with the presence of activating mutations in the KRAS and BRAF oncogenes as well as inactivating mutations in the TP53 tumor suppressor gene [18-20]. Whether similar genetic-epigenetic relationships might exist in other cancer types is yet to be determined. The difficulty in interpreting these studies lies in the fact that, at least in part, the analysis of human tumors is confounded by tremendous genetic variability, tumor heterogeneity, and difficulties in obtaining appropriate tissue controls [21,22]. As a result, a clear causal relationship between genetic mutation, hypermethylation, and tumor development has remained speculative. Here, we have taken advantage of mouse models of T cell lymphoma to explore epigenetic alterations in normal, premalignant, and cancer cells and demonstrate that DNA methylation patterns are dependent on the genetic mutation spectrum present in a tumor cell.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
###xml 45 50 <span type="species:ncbi:10090">Mouse</span>
A CpG Island Hypermethylation Signature in a Mouse Model of T Cell Lymphoma
###end title 9
###begin p 10
###xml 162 165 162 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b023">23</xref>
###xml 287 290 287 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 363 371 363 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-MYC</italic>
###xml 530 539 526 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA</italic>
###xml 545 553 540 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g001">Figure 1</xref>
###xml 555 556 550 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</italic>
###xml 643 651 638 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-MYC</italic>
###xml 849 852 844 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 955 973 950 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 131 136 <span type="species:ncbi:10090">mouse</span>
###xml 281 286 <span type="species:ncbi:9606">human</span>
###xml 721 725 <span type="species:ncbi:10090">mice</span>
###xml 881 886 <span type="species:ncbi:9606">human</span>
###xml 974 978 <span type="species:ncbi:10090">mice</span>
###xml 1009 1014 <span type="species:ncbi:10090">mouse</span>
To study the epigenetic evolution that normal cells experience on the path to a fully malignant state, we exploited a bitransgenic mouse model in which inducible MYC overexpression leads to the development of T cell lymphomas [23]. In this system, the first transgene contains the human MYC cDNA under the control of the tetracycline-responsive minimal promoter (Teto-MYC) and the second transgene expresses the tetracycline activator protein under the control of the immunoglobulin heavy chain enhancer and the SRalpha promoter (EmuSR-tTA; see Figure 1A). In the absence of doxycycline, tTA is expressed and mediates the transcription of the Teto-MYC transgene in approximately 30% of T cells. As a result, bitransgenic mice develop immature T cell lymphomas with lymph and splenic invasion and succumb to disease by 5 mo of age. Overexpression of MYC is a common feature of many human cancers, including Burkitt's lymphoma. The analysis of bitransgenic EmuSR-tTA;Teto-MYC mice may thus represent a suitable mouse model to evaluate the effect of a single oncogenic event on the epigenome of a tumor cell.
###end p 10
###begin title 11
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
Signature of Aberrant DNA Methylation in MYC-Induced T cell Lymphomas
###end title 11
###begin p 12
###xml 46 49 46 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
(A) Schematic representation of transgenes in MYC-induced T cell lymphoma model used in this study.
###end p 12
###begin p 13
###xml 51 60 51 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA</italic>
###xml 85 103 84 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
(B) Examples of RLGS profiles obtained from normal EmuSR-tTA thymocytes (normal) and EmuSR-tTA;Teto-MYC tumors (tumor). Loss or decreased intensity of single-copy NotI fragments in the tumors, relative to several neighboring unaltered fragments, was detected by visual inspection of overlaid autoradiographs. The arrows indicate the position of RLGS fragments 4E41, 2E46, 4B22, and 4D09, which are lost or reduced in intensity in tumor samples, indicative of specific methylation events.
###end p 13
###begin p 14
###xml 451 455 450 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFP</sup>
###xml 413 455 413 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXP<sup>EGFP</sup></italic>
###xml 490 498 489 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g002">Figure 2</xref>
###xml 456 460 <span type="species:ncbi:10090">mice</span>
(C) Summary of the frequency of methylation events observed in eight tumor samples and two normal thymic controls. Filled boxes indicate methylation at that site and open boxes indicate no methylation. Only data for RLGS fragments that have been methylated in more than 50% of tumors are shown. Methylation data from the analysis of three sets of EGFP-positive and EGFP-negative thymocytes isolated from 21-d-old EmuSR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXPEGFP mice are also shown (see text and Figure 2).
###end p 14
###begin p 15
###xml 137 146 137 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA</italic>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
(D) Southern blot analysis of control and tumor cells using the 2C51 NotI-EcoRV DNA fragment as a probe. DNA isolated from thymocytes of EmuSR-tTA mice was digested either with EcoRV alone (lane 1) or with EcoRV and NotI (lanes 2 and 3). DNA isolated from eight different T cell lymphomas (tumors; lanes 1-8) was digested with restriction enzymes EcoRV and NotI. The bands represent methylated (M) or unmethylated (U) NotI sites.
###end p 15
###begin p 16
(E) Schematic representation of a CpG island located near the RLGS fragment 3F56. Nucleotide position of the NotI site (black triangle), exon 1, and the region amplified for bisulfite sequencing is indicated relative to the transcription initiation site. Bisulfite sequencing was performed on DNA isolated from two normal and seven tumor samples. Each circle represents a CpG dinucleotide and each row of circles indicates the sequence of an individual allele. Filled black circles correspond to methylated CpG dinucleotides and open circles represent unmethylated CpG dinucleotides.
###end p 16
###begin p 17
###xml 111 120 111 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA</italic>
###xml 148 166 147 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 215 216 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
(F) Expression of genes near the RLGS fragments 2C51 and 3F56 was quantified in thymocytes isolated from three EmuSR-tTA mice (open bars) and eight EmuSR-tTA;Teto-MYC tumors (black bars) using real-time RT-PCR. The y-axis represents fold decrease in gene expression relative to the levels of gene expression detected in the first control.
###end p 17
###begin title 18
DNA Methylation Is Absent Early During Tumor Development
###end title 18
###begin p 19
(A) Schematic representation of experimental design used in this study.
###end p 19
###begin p 20
###xml 42 46 41 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFP</sup>
###xml 4 46 4 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXP<sup>EGFP</sup></italic>
###xml 277 281 275 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFP</sup>
###xml 239 281 238 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXP<sup>EGFP</sup></italic>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
(B) EmuSR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXPEGFP mice were harvested at 21 d of age, and EGFP-positive and EGFP-negative thymocytes were isolated using high-speed FACS. Flow diagrams for nontransgenic controls (EGFP-control), as well as for EmuSR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXPEGFP thymocytes prior to sorting (unsorted), and after sorting (EGFP-negative [-] and EGFP-positive [+] cells) are shown. The purity of EGFP-negative and EGFP-positive populations sorted from either side of the threshold, which is indicated with dotted lines, is shown within each panel.
###end p 20
###begin p 21
###xml 33 36 33 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 41 50 41 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nucleolin</italic>
###xml 52 55 52 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nuc</italic>
###xml 232 236 231 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFP</sup>
###xml 194 236 194 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXP<sup>EGFP</sup></italic>
###xml 259 267 258 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g002">Figure 2</xref>
###xml 237 242 <span type="species:ncbi:10090">mouse</span>
(C) Real-time RT-PCR analysis of MYC and nucleolin (nuc) expression in unsorted (gray bars), EGFP-positive (black bars) and EGFP-negative (white bars) cell populations sorted from thymocytes of EmuSR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXPEGFP mouse as described in Figure 2B. Expression data are presented as fold increase relative to the EGFP-negative population. Representative example from three independent experiments is shown.
###end p 21
###begin p 22
###xml 97 105 97 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g002">Figure 2</xref>
(D) Representative examples of RLGS profile sections derived from cells isolated as described in Figure 2B. The arrows indicate the position of RLGS fragments that appear methylated in tumors.
###end p 22
###begin p 23
###xml 166 174 166 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g002">Figure 2</xref>
(E) No differences in CpG methylation profiles between EGFP+ and EGFP- cell populations were detected for any of the three pairs of samples analyzed as summarized in Figure 2E where open boxes indicate no methylation at that site. Frequency of methylation events in final tumors for each RLGS fragment is shown as a percentage in corresponding boxes.
###end p 23
###begin p 24
###xml 128 143 <span type="species:ncbi:10090">transgenic mice</span>
(F) COBRA analysis of bisulfite-treated DNA isolated from EGFP-negative [-] and EGFP-positive [+] thymocytes of three quadruple transgenic mice at age 21 d. PCR products for RLGS fragment 3F70 were digested with restriction enzyme BstUI and loaded onto a PAGE gel along with 100% methylated (SssI-treated DNA) control (100%). DNA from normal thymocytes (con) and two tumors is also shown. Undigested and digested fragments correspond to unmethylated and methylated DNA, respectively.
###end p 24
###begin p 25
###xml 233 237 232 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFP</sup>
###xml 195 237 195 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXP<sup>EGFP</sup></italic>
(G) Expression of genes near the RLGS fragments as determined by real-time RT-PCR analysis of EGFP-negative (white bars) and EGFP-positive (black bars) cell populations sorted from thymocytes of EmuSR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXPEGFP. Expression of each gene in EGFP-positive population is presented as fold decrease relative to the expression of the same gene in EGFP-negative population. Representative examples from three independent experiments are shown.
###end p 25
###begin p 26
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC-</italic>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b015">15</xref>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b024">24</xref>
###xml 570 588 570 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 660 669 659 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA</italic>
###xml 882 891 880 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g001">Figures 1</xref>
###xml 893 894 891 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g001">1</xref>
###xml 1014 1016 1012 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p-</italic>
###xml 1111 1113 1109 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b015">15</xref>
###xml 1114 1116 1112 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b025">25</xref>
###xml 1117 1119 1115 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b027">27</xref>
###xml 1308 1310 1306 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b021">21</xref>
###xml 1396 1404 1394 1402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-st001">Table S1</xref>
###xml 1571 1580 1569 1578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g001">Figures 1</xref>
###xml 1586 1588 1584 1586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-sg001">S1</xref>
###xml 1590 1598 1588 1596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-st001">Table S1</xref>
###xml 1795 1804 1793 1802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g001">Figures 1</xref>
###xml 1807 1809 1805 1807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-sg001">S1</xref>
###xml 1815 1817 1813 1815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-sg002">S2</xref>
###xml 1819 1827 1817 1825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-st001">Table S1</xref>
###xml 2409 2418 2407 2416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g001">Figures 1</xref>
###xml 2424 2426 2422 2424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-sg001">S1</xref>
###xml 2428 2436 2426 2434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-st001">Table S1</xref>
###xml 2523 2526 2521 2524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 2692 2694 2690 2692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b015">15</xref>
###xml 589 593 <span type="species:ncbi:10090">mice</span>
###xml 670 674 <span type="species:ncbi:10090">mice</span>
###xml 1091 1096 <span type="species:ncbi:9606">human</span>
###xml 2517 2522 <span type="species:ncbi:10090">mouse</span>
###xml 2678 2683 <span type="species:ncbi:9606">human</span>
We evaluated CpG island methylation in these MYC-induced tumors by restriction landmark genomic scanning (RLGS), a two-dimensional gel electrophoresis that measures the DNA methylation status of about 1,500-2,000 NotI methylation-sensitive restriction enzyme sites preferentially located in CpG islands [15,24]. A loss or reduction of a radiolabeled NotI DNA fragment is indicative of DNA methylation at that site, whereas an increase is indicative of either hypomethylation or amplification. Initially, we compared DNA from eight late-stage lymphomas that developed in EmuSR-tTA;Teto-MYC mice and two control thymocyte samples derived from age-matched normal EmuSR-tTA mice. This comparison revealed that 137 of 2,206 possible CpG islands were hypermethylated in at least one tumor, with 59 loci hypermethylated in five or more tumors and seven loci hypermethylated in all tumors (Figures 1B-1D). Statistical evaluation using a standard goodness-of-fit test indicated a nonrandom distribution of DNA methylation (p-value < 0.0001), which is similar to what has previously been reported for human malignancies [15,25-27]. The identity of 79 of the 137 hypermethylated NotI/EcoRV fragments was determined by sequencing the corresponding clones from the arrayed NotI/EcoRV genomic library as described before [21]. Of these, 65 corresponded to CpG islands located within 5' regions of known genes (Table S1). Southern blot analysis of normal and tumor samples probed with the cloned DNA fragments confirmed tumor-specific hypermethylation in 14 of the 15 RLGS loci tested (Figures 1D and S1; Table S1). Bisulfite sequencing and combined bisulfite restriction analysis (COBRA) assays confirmed tumor-specific methylation in regions surrounding the NotI site in 29 out of the 34 CpG islands tested (Figures 1E, S1, and S2; Table S1). The discrepancy in the five CpG islands that were not confirmed by bisulfite-based methods may reflect assay-specific biases that rely on the utilization of different restriction endonuclease sites. Because hypermethylation is associated with gene silencing, we evaluated the expression of a subset of 16 genes corresponding to the hypermethylated CpG islands identified above. As determined by real-time reverse transcriptase PCR (RT-PCR) techniques, the expression of 15 from 16 randomly selected genes was significantly decreased in tumor samples relative to normal controls (Figures 1F and S1; Table S1). Together, these results identify a CpG island hypermethylation signature in a mouse MYC-induced lymphoma model that is associated with transcription repression and that has a similar frequency of altered methylation as previously found in human tumors [15].
###end p 26
###begin title 27
Absence of Aberrant DNA Methylation in Precancerous Cells
###end title 27
###begin p 28
###xml 123 126 123 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 308 316 308 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g002">Figure 2</xref>
###xml 407 415 407 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-MYC</italic>
###xml 729 732 717 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 855 859 843 847 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFP</sup>
###xml 836 859 824 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-Cre;Rosa26LOXP<sup>EGFP</sup></italic>
###xml 921 925 908 912 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFP</sup>
###xml 883 925 871 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXP<sup>EGFP</sup></italic>
###xml 958 966 945 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g001">Figure 1</xref>
###xml 994 1002 981 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-Cre</italic>
###xml 1094 1098 1081 1085 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFP</sup>
###xml 1084 1098 1071 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rosa26LOXP<sup>EGFP</sup></italic>
###xml 1160 1169 1147 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA</italic>
###xml 1185 1193 1171 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-MYC</italic>
###xml 1198 1206 1184 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-Cre</italic>
###xml 1262 1265 1248 1251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 1267 1271 1253 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cre,</italic>
###xml 1276 1280 1262 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFP</italic>
###xml 1335 1343 1321 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g002">Figure 2</xref>
###xml 1613 1616 1599 1602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 1685 1694 1671 1680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nucleolin</italic>
###xml 1720 1729 1706 1715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g002">Figures 2</xref>
###xml 1732 1734 1718 1720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-sg004">S4</xref>
###xml 1740 1742 1726 1728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-sg004">S4</xref>
###xml 1925 1928 1911 1914 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 2028 2036 2014 2022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g002">Figure 2</xref>
###xml 2042 2043 2028 2029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g002">2</xref>
###xml 2188 2197 2174 2183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g002">Figures 2</xref>
###xml 2203 2205 2189 2191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-sg003">S3</xref>
###xml 2207 2209 2193 2195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-sg003">S3</xref>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
###xml 553 557 <span type="species:ncbi:10090">mice</span>
###xml 811 815 <span type="species:ncbi:10090">mice</span>
###xml 869 873 <span type="species:ncbi:10090">mice</span>
###xml 1467 1482 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1888 1892 <span type="species:ncbi:10090">mice</span>
To determine whether this tumor-specific methylation signature is established early in the neoplastic process, we examined MYC overexpressing cells in young mice prior to clonal expansion of precancerous cells and the manifestation of overt disease, as well as in mice manifesting early symptoms of disease (Figure 2A and unpublished data). At 21 and 31 d of age, bitransgenic mice are asymptomatic and the Teto-MYC transgene is expressed in only a portion (approximately30%) of total thymocytes (unpublished data). By 42 d of age, the vast majority of mice show early signs of tumor progression, such as increased thymic cellularity and changes in the expression of cell surface markers such as CD4, CD8, and CD3. To enrich for MYC-expressing cells and minimize contamination from normal T cells, bitransgenic mice were interbred with Teto-Cre;Rosa26LOXPEGFP reporter mice to yield EmuSR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXPEGFP quadruple transgenic offspring (Figure 1A). Cre expression from the Teto-Cre transgene results in the excision of the "stop cassette" located upstream of the Rosa26LOXPEGFP locus and synthesis of EGFP. Thus, accumulation of tTA (from EmuSR-tTA) activates the Teto-MYC and Teto-Cre transgenes and leads to the simultaneous expression of MYC, Cre, and EGFP within the same subpopulation of T cells. As shown in Figure 2B, fluorescent activated cell sorting (FACS)-based cell sorting of thymocytes isolated from 21-, 31- and 42-d-old quadruple transgenic mice resulted in the efficient separation of EGFP-positive and EGFP-negative thymocytes. As expected, there was a marked enrichment of MYC expression as well as one of its bona fide transcriptional targets, nucleolin, in EGFP-positive cells (Figures 2C, S4A and S4D). Surprisingly, the RLGS patterns of DNA methylation in three pairs of EGFP-positive and EGFP-negative cells derived from 21-, 31- and 42-d-old mice were identical, indicating that MYC overexpression in thymocytes is not sufficient to target hypermethylation to specific CpG islands (Figure 2D and 2E; unpublished data). The absence of aberrant promoter methylation at these early stages of disease was confirmed by gene-specific COBRA assays (Figures 2F and S3A-S3C).
###end p 28
###begin p 29
###xml 360 364 359 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFP</sup>
###xml 322 364 322 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXP<sup>EGFP</sup></italic>
###xml 481 490 480 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g002">Figures 2</xref>
###xml 493 495 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-sg004">S4</xref>
###xml 502 504 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-sg004">S4</xref>
###xml 610 613 609 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 870 873 869 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 365 369 <span type="species:ncbi:10090">mice</span>
Because promoter methylation can potentially represent a consequence of long-term repression, we measured during these early stages of lymphomagenesis the expression of genes that are typically repressed at late stages of disease. Analysis of EGFP-negative and EGFP-positive thymocytes isolated from 21-, 31- and 42-d-old EmuSR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXPEGFP mice revealed no significant differences in the expression of the thirteen genes evaluated by real time PCR assays (Figures 2G, S4B, and S4E). The fact that aberrant DNA methylation and gene repression can only be detected during late stages of MYC-induced lymphomagenesis, once a pretumor cell has clonally expanded to the entire thymus and/or the periphery, suggests that rare DNA methylation events arise (or are selected for) during the course of tumor development and are not a direct consequence of MYC over-expression.
###end p 29
###begin title 30
###xml 106 111 <span type="species:ncbi:10090">Mouse</span>
Overlapping CpG Island Hypermethylation Signatures Selected During In Vitro and In Vivo Transformation of Mouse Embryonic Fibroblasts
###end title 30
###begin p 31
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b028">28</xref>
###xml 189 207 189 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 796 799 795 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 825 828 824 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ras</italic>
###xml 833 836 832 835 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">61L</sup>
###xml 830 836 829 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ras<sup>61L</sup></italic>
###xml 964 967 963 966 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">61L</sup>
###xml 957 967 956 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC/Ras<sup>61L</sup></italic>
###xml 986 994 985 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g003">Figure 3</xref>
###xml 996 997 995 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g003">3</xref>
###xml 1023 1041 1022 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 1048 1051 1046 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 1353 1356 1351 1354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">61L</sup>
###xml 1346 1356 1344 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC/Ras<sup>61L</sup></italic>
###xml 1493 1501 1491 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g003">Figure 3</xref>
###xml 1576 1579 1574 1577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">61L</sup>
###xml 1569 1579 1567 1577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC/Ras<sup>61L</sup></italic>
###xml 1726 1734 1724 1732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g003">Figure 3</xref>
###xml 1740 1741 1738 1739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g003">3</xref>
###xml 1786 1789 1784 1787 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">61L</sup>
###xml 1779 1789 1777 1787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Myc/Ras<sup>61L</sup></italic>
###xml 2103 2106 2101 2104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">61L</sup>
###xml 2096 2106 2094 2104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC/Ras<sup>61L</sup></italic>
###xml 529 534 <span type="species:ncbi:10090">mouse</span>
###xml 1042 1046 <span type="species:ncbi:10090">mice</span>
###xml 1449 1458 <span type="species:ncbi:10090">nude mice</span>
###xml 1715 1724 <span type="species:ncbi:10090">nude mice</span>
###xml 2019 2028 <span type="species:ncbi:10090">nude mice</span>
Lymphomas are thought to arise from the expansion of a small pool of cancer-initiating cells [28]. Because the cellular compartment from which tumor cells arise has not been defined in the EmuSR-tTA;Teto-MYC model, it is impossible to ascertain the DNA methylation status of the genome in these cells. Thus, to evaluate CpG island methylation in a more homogenous and experimentally amenable cell system where the chronology of aberrant DNA methylation could be better evaluated during the early neoplastic process, we turned to mouse embryonic fibroblasts (MEFs). Primary MEFs have the potential to be transformed in vitro and in vivo by the cointroduction of two oncogenes. We thus compared DNA methylation by RLGS methods in primary MEFs before and immediately after their transformation with MYC and an activated form of Ras (Ras61L). This comparison of 1,635 NotI restriction sites revealed no methylation changes between control and fully transformed MYC/Ras61L-expressing cells (Figure 3A-3C), suggesting that as in EmuSR-tTA;Teto-MYC mice, MYC expression and transformation of MEFs is not sufficient to target methylation to specific CpG islands. We then assessed whether signatures of CpG island methylation could be acquired or selected for when transformed MEFs are cultured for longer periods of time. DNA methylation was analyzed in MYC/Ras61L-transformed MEFs that were either cultured in vitro for several weeks or were injected into nude mice for an equivalent length of time (Figure 3A). Approximately 17 NotI sites were found to be hypermethylated in MYC/Ras61L-transformed MEFs cultured in vitro and an additional seven NotI sites were hypermethylated in tumor cells that emerged in the injected nude mice (Figure 3B and 3C). These data suggest that among all Myc/Ras61L-expressing MEFs with a fully transformed phenotype, only those with a specific pattern of methylated CpG islands are favored during their in vitro or in vivo expansion. The additional DNA methylation events observed in tumors in nude mice presumably reflect the additional level of selection pressure that MYC/Ras61L-transformed cells were exposed to in the in vivo setting.
###end p 31
###begin title 32
###xml 73 76 73 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Myc</italic>
###xml 81 84 81 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ras</italic>
###xml 28 33 <span type="species:ncbi:10090">Mouse</span>
Aberrant DNA Methylation in Mouse Embryonic Fibroblasts Transformed with Myc and Ras
###end title 32
###begin p 33
###xml 224 227 224 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 253 256 253 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ras</italic>
###xml 261 264 261 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">61L</sup>
###xml 258 264 258 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ras<sup>61L</sup></italic>
###xml 469 478 <span type="species:ncbi:10090">nude mice</span>
(A) Schematic representation of experimental design used for evaluation of in vitro and in vivo DNA methylation in MEFs. Early passage of primary MEFs was either harvested (C0) or infected with retroviral vectors expressing MYC and an activated form of Ras (Ras61L). A portion of cells was harvested immediately after transformation had occurred, as determined by morphological changes (C1). At this point, the rest of the cells was either injected subcutaneously into nude mice or kept in culture. By 18 d, injected cells formed tumors that were harvested along with C1 cells kept in culture in vitro (T2 tumor and C2 culture, respectively).
###end p 33
###begin p 34
###xml 152 161 <span type="species:ncbi:10090">nude mice</span>
(B) Methylation status of 1,635 NotI restriction sites was evaluated by RLGS in DNA from C0, C1, and C2 cultures along with five T2 tumors derived from nude mice. The Venn diagram shows the number of NotI fragments that became methylated in T2 culture and T2 tumors. Sections of RLGS profiles are shown for fragments 3B29 and 4F01.
###end p 34
###begin p 35
(C) Summary of DNA methylation changes observed in C0, C1, and C2 culture and five T2 tumors as determined by RLGS. Open squares represent unmethylated sequences, black squares represent methylated events.
###end p 35
###begin title 36
Tumor Suppressor Function Drives the Specificity of CpG Island Methylation
###end title 36
###begin p 37
Aberrant DNA methylation in T cell tumors could result from rare random events selected for in neoplastic cells, from specific defects in the DNA methylation process, from intrinsic sequences predisposing to DNA methylation, or a combination of all three. Genes that are methylated and silenced in cancer are likely to be involved in specific pathways impacting any number of important processes, including proliferation, differentiation, and apoptosis. We reasoned that if DNA methylation events are selected for in neoplastic cells, and therefore contribute to the neoplastic process, the inactivation of key tumor suppressors impacting one or more of these same processes might diminish the selective pressure imposed during neoplastic progression. The inactivation of tumor suppressor function would thus be predicted to change the specific DNA methylation signature acquired by tumor cells.
###end p 37
###begin p 38
###xml 99 117 99 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 142 145 141 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 147 152 146 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten,</italic>
###xml 156 160 155 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 180 183 179 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P53</italic>
###xml 188 192 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 269 271 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b029">29</xref>
###xml 272 274 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b030">30</xref>
###xml 342 344 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b031">31</xref>
###xml 345 347 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b032">32</xref>
###xml 397 401 396 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 595 613 594 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 618 621 616 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 622 623 620 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 621 624 619 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 628 632 626 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 633 634 631 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 632 635 630 633 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 664 682 662 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 683 686 680 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 687 688 684 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 686 689 683 686 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 694 712 691 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 713 717 709 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 718 719 714 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 717 720 713 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 764 768 760 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 801 819 797 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 863 871 858 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-Cre</italic>
###xml 910 914 905 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 929 933 924 928 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LoxP</sup>
###xml 916 933 911 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-Cre;Pten<sup>LoxP</sup></italic>
###xml 986 1004 981 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 1018 1027 1012 1021 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LoxP/LoxP</sup>
###xml 1005 1027 999 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-Cre;Pten<sup>LoxP/LoxP</sup></italic>
###xml 1092 1095 1086 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1097 1101 1091 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1106 1110 1100 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 1158 1159 1152 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1169 1170 1163 1164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1184 1185 1178 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1210 1218 1204 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g004">Figure 4</xref>
###xml 1381 1389 1375 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g004">Figure 4</xref>
###xml 1478 1487 1472 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g004">Figures 4</xref>
###xml 1493 1494 1487 1488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g005">5</xref>
###xml 1636 1655 1630 1648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA; Teto-MYC</italic>
###xml 1662 1663 1655 1656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</italic>
###xml 1673 1697 1666 1689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA; Teto-MYC; p53</italic>
###xml 1698 1699 1690 1691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 1697 1700 1689 1692 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 1709 1710 1701 1702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1762 1771 1753 1762 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LoxP/LoxP</sup>
###xml 1728 1771 1720 1762 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA; Teto-MYC; Teto-Cre;Pten<sup>LoxP/LoxP</sup></italic>
###xml 1773 1774 1764 1765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1783 1784 1774 1775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</italic>
###xml 1797 1822 1788 1812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA; Teto-MYC; E2f2</italic>
###xml 1823 1824 1813 1814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 1822 1825 1812 1815 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 1827 1828 1817 1818 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1949 1962 1939 1951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;p53</italic>
###xml 1963 1964 1952 1953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 1962 1965 1951 1954 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 1990 1999 1978 1987 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LoxP/LoxP</sup>
###xml 1965 1999 1954 1987 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, E&#956;SR-tTA;Teto-Cre;Pten<sup>LoxP/LoxP</sup></italic>
###xml 2004 2018 1992 2005 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;E2f2</italic>
###xml 2019 2020 2006 2007 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 2018 2021 2005 2008 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 2317 2326 2304 2313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-sg005">Figure S5</xref>
###xml 255 260 <span type="species:ncbi:9606">human</span>
###xml 455 460 <span type="species:ncbi:9606">human</span>
###xml 504 508 <span type="species:ncbi:10090">mice</span>
###xml 636 640 <span type="species:ncbi:10090">mice</span>
###xml 820 824 <span type="species:ncbi:10090">mice</span>
###xml 845 849 <span type="species:ncbi:10090">mice</span>
###xml 1028 1032 <span type="species:ncbi:10090">mice</span>
###xml 1284 1288 <span type="species:ncbi:10090">mice</span>
###xml 2022 2026 <span type="species:ncbi:10090">mice</span>
To test this prediction, we evaluated CpG island methylation in T cell lymphomas that developed in EmuSR-tTA;Teto-MYC animals deleted for the p53, Pten, or E2f2 tumor suppressors. P53 and PTEN are the most frequently inactivated tumor suppressor genes in human cancer [29,30] and have been shown to have tumor suppressor function in T cells [31,32]. Recent studies in our laboratory indicate that E2f2 expression is significantly decreased in a number of human hematopoietic malignancies and its loss in mice accelerates T cell lymphomagenesis (G. L., unpublished data). Therefore, we interbred EmuSR-tTA;Teto-MYC and p53-/- or E2f2-/- mice to generate cohorts of EmuSR-tTA;Teto-MYC;p53-/- and EmuSR-tTA;Teto-MYC;E2f2-/- animals. Because germ line inactivation of Pten results in embryonic lethality, EmuSR-tTA;Teto-MYC mice were interbred with mice carrying the Teto-Cre transgene and a conditional allele of Pten (Teto-Cre;PtenLoxP). From these latter crosses we generated cohorts of EmuSR-tTA;Teto-MYC;Teto-Cre;PtenLoxP/LoxP mice. Consistent with their tumor suppressor functions, loss of p53, Pten, or E2f2 significantly accelerated disease progression (p = 0.001; p = 0.005, and p = 0.0007, respectively; Figure 4A). In each case, FACS analysis confirmed that lymphomas in these mice were of T cell origin and consisted of either CD4 single- or CD4/CD8 double-positive cells (Figure 4B). We then analyzed the pattern of CpG island methylation in each tumor cohort by RLGS (Figures 4C and 5A). All four tumor groups had significant amounts of promoter hypermethylation; with an average of 1.8% of CpG islands hypermethylated in the EmuSR-tTA; Teto-MYC cohort, 1.1 % in EmuSR-tTA; Teto-MYC; p53-/- cohort (p = 0.06), 0.3% in EmuSR-tTA; Teto-MYC; Teto-Cre;PtenLoxP/LoxP (p = 0.004), and 1.9% in EmuSR-tTA; Teto-MYC; E2f2-/- (p = 0.885). Importantly, there was no detectable aberrant DNA methylation in control thymocytes isolated from age-matched EmuSR-tTA;p53-/-, EmuSR-tTA;Teto-Cre;PtenLoxP/LoxP, or EmuSR-tTA;E2f2-/- mice (unpublished data). The aberrant DNA methylation detected in tumor samples was confirmed by 126 COBRA reactions performed on the same tumor samples that were used for RLGS analysis. This analysis revealed that in 74% of the cases evaluated, RLGS and COBRA assays yielded identical results (Figure S5 and unpublished data). In 22 % of cases COBRA detected aberrant DNA methylation events that were not identified by RLGS. This is not surprising, since COBRA is a more sensitive method to detect DNA methylation. In 4% of cases, COBRA assays failed to detect DNA methylation events that were detected by RLGS; this discrepancy likely reflects the different restriction sites analyzed by these methods.
###end p 38
###begin title 39
###xml 40 43 40 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
Analysis of Aberrant DNA Methylation in p53-, E2f2-, and Pten-Deleted Lymphomas
###end title 39
###begin p 40
###xml 65 83 65 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 97 115 96 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 116 119 114 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 120 121 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 119 122 117 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 124 127 122 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 128 129 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 127 130 125 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 133 151 131 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 152 156 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 157 158 154 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 156 159 153 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 161 165 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 166 167 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 165 168 162 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 174 192 171 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 206 215 202 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LoxP/LoxP</sup>
###xml 193 215 189 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-Cre;Pten<sup>LoxP/LoxP</sup></italic>
###xml 217 221 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 222 223 218 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 221 224 217 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 230 231 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</italic>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
(A) Graphical representation of the time-frame of tumor onset in EmuSR-tTA;Teto-MYC (wild type), EmuSR-tTA;Teto-MYC;p53-/- (p53-/-), EmuSR-tTA;Teto-MYC;E2f2-/- (E2f2-/-), or EmuSR-tTA;Teto-MYC;Teto-Cre;PtenLoxP/LoxP (Pten-/-) mice.
###end p 40
###begin p 41
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</italic>
(B) Examples of FACS profiles of normal thymocytes (normal) and tumor cells (tumors) derived from the different genetic backgrounds as indicated. The percentage of cells that are in each quadrant of the FACS profile is indicated.
###end p 41
###begin p 42
###xml 87 96 87 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA</italic>
###xml 108 111 107 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 105 111 104 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53<sup>+/+</sup></italic>
###xml 117 126 116 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA</italic>
###xml 128 131 126 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 132 133 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 131 134 129 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 143 146 141 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 147 148 145 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 146 149 144 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 180 189 178 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA</italic>
###xml 190 198 187 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-MYC</italic>
###xml 209 212 206 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 206 212 203 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53<sup>+/+</sup></italic>
###xml 218 227 215 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA</italic>
###xml 228 241 224 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-MYC; p53</italic>
###xml 242 243 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 241 244 237 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 252 255 248 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 256 257 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 255 258 251 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 395 398 391 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 428 431 424 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 425 431 421 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53<sup>+/+</sup></italic>
###xml 436 439 432 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 440 441 436 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 439 442 435 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 260 264 <span type="species:ncbi:10090">mice</span>
(C) Representative examples of RLGS profile sections of normal thymocytes derived from EmuSR-tTA (normal p53+/+) and EmuSR-tTA; p53-/- (normal p53-/-) mice and tumors derived from EmuSR-tTA;Teto-MYC (tumor p53+/+) and EmuSR-tTA;Teto-MYC; p53-/- (tumor p53-/-) mice. The position of DNA fragment 2D17 is indicated with arrows. Note the increase in the intensity of 2D17 in tumors deleted for the p53 tumor suppressor (compare p53+/+ and p53-/- tumor samples in the third and fourth panels).
###end p 42
###begin p 43
###xml 92 110 92 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 135 153 134 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 180 183 178 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 185 189 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 194 198 192 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
(D) Real time RT-PCR analysis of expression of 6D20 in normal thymic controls (white bars), EmuSR-tTA;Teto-MYC tumors (black bars), or EmuSR-tTA;Teto-MYC tumors deleted either for p53, E2f2, or Pten (grey bars) as indicated.
###end p 43
###begin p 44
(E) Summary of expression data from tumors derived in different genetic backgrounds obtained on analysis of eight RLGS fragments as indicated. Red boxes represent tumors with reduction in expression relative to normal thymic controls; yellow boxes indicate tumors with no change in expression. Repression thresholds for individual genes were chosen as described in Materials and Methods.
###end p 44
###begin title 45
Loss of Tumor Suppressor Genes Redirects the Course of Aberrant DNA Methylation
###end title 45
###begin p 46
###xml 69 78 69 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA</italic>
###xml 79 91 78 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-MYC;p53</italic>
###xml 92 93 91 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 91 94 90 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 96 106 95 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left panel</italic>
###xml 109 127 108 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 128 132 126 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 133 134 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 132 135 130 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 156 174 154 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 189 198 186 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LoxP/LoxP</sup>
###xml 176 198 173 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-Cre;Pten<sup>LoxP/LoxP</sup></italic>
###xml 230 239 227 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA</italic>
###xml 240 248 236 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-MYC</italic>
###xml 271 274 267 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 268 274 264 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53<sup>+/+</sup></italic>
###xml 280 283 276 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 276 283 272 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2<sup>+/+</sup></italic>
###xml 293 296 289 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 289 296 285 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>+/+</sup></italic>
###xml 663 672 659 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA</italic>
###xml 673 676 668 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 677 678 672 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 676 679 671 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 699 713 694 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;E2f2</italic>
###xml 714 715 708 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 713 716 707 710 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 719 720 713 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 765 774 758 767 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LoxP/LoxP</sup>
###xml 742 774 736 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-Cre;Pten<sup>LoxP/LoxP</sup></italic>
###xml 851 852 844 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 213 217 <span type="species:ncbi:10090">mice</span>
###xml 249 253 <span type="species:ncbi:10090">mice</span>
###xml 794 798 <span type="species:ncbi:10090">mice</span>
(A) Comparison of tumor-specific DNA methylation changes observed in EmuSR-tTA;Teto-MYC;p53-/- (left panel), EmuSR-tTA;Teto-MYC;E2f2-/- (middle panel), and EmuSR-tTA;Teto-MYC; Teto-Cre;PtenLoxP/LoxP (right panel) mice relative to EmuSR-tTA;Teto-MYC mice (indicated as p53+/+, E2f2+/+, and Pten+/+ in each of the panels). Data is shown for RLGS fragments methylated in >33% of tumors. Filled boxes indicate methylation and open boxes indicate a loss of methylation at those sites. Class I, Class II, and Class III RLGS DNA fragments are outlined in green, red, and blue, respectively). Data from analysis of thymocytes isolated from two age-matched normal control EmuSR-tTA;p53-/- (-/-; left panel), EmuSR-tTA;E2f2-/- (-/-; middle panel), and EmuSR-tTA;Teto-Cre;PtenLoxP/LoxP (-/-; right panel) mice are also shown. Fisher's exact test was applied and p-values are shown.
###end p 46
###begin p 47
###xml 161 179 161 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 182 185 181 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 187 205 186 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 207 210 205 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 210 213 208 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 216 220 214 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 222 240 220 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 242 246 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 246 249 243 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 255 259 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 261 279 258 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 294 303 290 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LoxP/LoxP</sup>
###xml 281 303 277 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-Cre;PTEN<sup>LoxP/LoxP</sup></italic>
###xml 304 305 300 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</italic>
(B) Dendrogram of a two-dimensional unsupervised hierarchical cluster analysis for 28 tumors analyzed using methylation status of 1,481 NotI fragments. Control (EmuSR-tTA;Teto-MYC), p53 (EmuSR-tTA;Teto-MYC; p53-/-), E2f2 (EmuSR-tTA;Teto-MYC; E2f2-/-), or Pten (EmuSR-tTA;Teto-MYC; Teto-Cre;PTENLoxP/LoxP).
###end p 47
###begin p 48
###xml 155 163 155 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g005">Figure 5</xref>
###xml 854 862 854 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g005">Figure 5</xref>
###xml 1064 1068 1064 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6D20</italic>
###xml 1114 1116 1114 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MY</italic>
###xml 1198 1207 1198 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2, p53</italic>
###xml 1212 1216 1212 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 1218 1226 1218 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g004">Figure 4</xref>
###xml 1454 1462 1454 1462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g004">Figure 4</xref>
###xml 1625 1628 1625 1628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1629 1630 1629 1630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 1628 1631 1628 1631 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
Side-by-side comparison of DNA methylation profiles between deleted and nondeleted tumor groups could distinguish three classes of DNA methylation events (Figure 5A). The first class included aberrant DNA methylation events that were common between deleted and nondeleted tumor cohorts, with methylation of some CpG islands occurring in all tumor groups irrespective of the particular tumor suppressor deleted. The second class consisted of aberrant DNA methylation events that were suppressed by loss of tumor suppressor function, with some DNA methylation events suppressed only in specific tumor suppressor cohorts and others events suppressed in all tumor suppressor cohorts. Conversely, the third class consisted of novel DNA methylation events that occurred in tumors as a result of tumor suppressor inactivation (Class I, Class II, and Class III; Figure 5A). An evaluation of gene expression in each tumor suppressor cohort indicated that suppression of promoter methylation correlates well with their reactivation of expression. For example, expression of 6D20, which was methylated and silenced in 50% of MYC-initiated tumors, was preferentially reactivated in tumors deficient either for E2f2, p53, or PTEN (Figure 4D). Similarly, expression of seven additional genes corresponding to RLGS fragments 2G81, 3F45, 3F56, 4B22, 1G05-06, 1D14, and 6C25 correlated well with the methylation status of CpG islands in each corresponding genetic group (Figure 4E). Additional genetic changes in the evolving tumors likely account for the few cases where expression and DNA methylation profiles did not correspond (see 1D14, p53-/- for an example). These data suggest that tumor suppressor-specific patterns of CpG island methylation correspond with global gene expression profiles.
###end p 48
###begin p 49
###xml 251 254 251 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 255 256 255 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 254 257 254 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 259 263 259 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 264 265 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 263 266 263 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 272 276 272 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 277 278 277 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 276 279 276 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 320 329 320 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-sg006">Figure S6</xref>
###xml 505 513 505 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g005">Figure 5</xref>
###xml 674 682 674 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g005">Figure 5</xref>
###xml 828 836 828 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g005">Figure 5</xref>
###xml 910 918 910 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-st004">Table S4</xref>
###xml 1382 1386 1382 1386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1471 1472 1471 1472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1572 1576 1572 1576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1577 1578 1577 1578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 1576 1579 1576 1579 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 1650 1654 1650 1654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1763 1765 1763 1765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b033">33</xref>
###xml 2046 2049 2046 2049 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 2053 2057 2053 2057 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
As a measure of CpG methylation specificity provoked by the inactivation of individual tumor suppressor pathways, we performed a two-dimensional unsupervised hierarchical cluster analysis. This unbiased analysis of DNA methylation identified deleted (p53-/-, Pten-/-, and E2f2-/-) and nondeleted tumor groups correctly (Figure S6). Strikingly, unsupervised hierarchical clustering performed with all tumor samples together led to an almost perfect segregation of tumors based on their genetic background (Figure 5B). While the entire constellation of methylation changes (or lack thereof) can serve to discriminate between genetic groups, it is clear from the data shown in Figure 5A that different methylation events contribute to different degrees. The contribution of each DNA methylation event to the clustering observed in Figure 5B was evaluated by a Random Forrest analysis and statistical ranking (see Table S4). Two important conclusions can be drawn from these experiments. The first and perhaps most obvious of these is that loss of tumor suppressor functions yield specific profiles of CpG island methylation in cancer. We view these results to mean that different tumor suppressor pathways impose unique selective pressures on neoplastic cells that drive the specificity of CpG island methylation. Interestingly, the overall frequency of hypermethylated CpG islands in Pten-deficient tumors was substantially less than seen in the other tumor cohorts (0.3%, p = 0.004), suggesting a particularly strong diversion of the selective pressure in the evolution of Pten-/- tumors. This suppression of tumor-specific DNA methylation by loss of Pten is likely a reflection of the broader number of pathways that Pten action impacts to prevent tumorigenesis [33]. The second conclusion is that the specificity of CpG island methylation is not likely to be a consequence of a general defect in the DNA methylation machinery since the specific profile, but not the frequency, of tumor-dependent CpG methylation events is altered by the loss of p53 or E2f2.
###end p 49
###begin title 50
Discussion
###end title 50
###begin p 51
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b034">34</xref>
###xml 1068 1071 1068 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1073 1077 1073 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1082 1086 1082 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 1090 1093 1090 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 1479 1480 1479 1480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b004">4</xref>
###xml 1481 1483 1481 1483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b015">15</xref>
###xml 155 160 <span type="species:ncbi:10090">mouse</span>
###xml 316 321 <span type="species:ncbi:9606">human</span>
###xml 430 435 <span type="species:ncbi:10090">mouse</span>
###xml 658 663 <span type="species:ncbi:10090">mouse</span>
###xml 933 938 <span type="species:ncbi:9606">human</span>
###xml 1465 1470 <span type="species:ncbi:9606">human</span>
In this study, we have investigated the interplay between genetic mutations and the establishment of global DNA methylation patterns in the development of mouse T cell lymphomas. The model used here, developed by Felsher and colleagues, uses high levels of MYC expression to mimic similar events taking place during human lymphomagenesis such as in Burkitt's lymphoma ([34] and references therein). The clear advantage of using a mouse model to study the role of DNA methylation in cancer is that cohorts used are genetically homogeneous in all respects except on a defined set of genetic variables (i.e., overexpression of MYC). Therefore, we consider this mouse model to be suitable for studying the relationship between genetic and epigenetic changes during tumor development. We demonstrate that DNA methylation patterns in these tumors are characterized by frequent and nonrandom patterns, similar to what has been described in human malignancies. These patterns are exquisitely dependent on the genetic makeup of the tumor cell, as homozygous deletion of either p53, Pten, or E2f2 in MYC-induced T cell lymphomas resulted in unique tumor-specific patterns of genome-wide DNA methylation. This analysis provides the first clear-cut experimental evidence showing that genetic background can drive the establishment of aberrant DNA methylation profiles during lymphoma development, offering an explanation for the tremendous epigenetic heterogeneity observed in human cancer [4,15].
###end p 51
###begin p 52
###xml 186 187 186 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b008">8</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b010">10</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b012">12</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b013">13</xref>
###xml 410 413 410 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 962 965 962 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 973 976 973 976 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">61L</sup>
###xml 970 976 970 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ras<sup>61L</sup></italic>
###xml 1056 1059 1056 1059 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">61L</sup>
###xml 1049 1059 1049 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC/Ras<sup>61L</sup></italic>
###xml 97 102 <span type="species:ncbi:9606">human</span>
###xml 1165 1174 <span type="species:ncbi:10090">nude mice</span>
###xml 1421 1426 <span type="species:ncbi:10090">mouse</span>
Multiple mechanisms have been proposed to explain the specificity of aberrant DNA methylation in human cancer, including the differential susceptibility of DNA sequences to methylation [8-10] and the targeting of methyltransferase activity to specific promoter sequences [12,13]. The fact that our RLGS analysis identified a specific signature of CpG island methylation that could only be detected late in the MYC-induced neoplastic process suggests that MYC overexpression is insufficient to target the DNA methylation machinery to specific sites. It is unlikely that the absence of aberrant promoter methylation early in the neoplastic process was due to the notoriously slow nature of de novo methylation relative to the kinetics of gene repression, since repression was not observed at these early stages of disease, either. This view is further supported by the absence of any hypermethylation signature in cells immediately following the transformation by MYC and Ras61L. Rather, specific patterns of DNA methylation could only be detected in MYC/Ras61L-transformed MEFs that have been either cultured in vitro for an extended period of time or injected into nude mice for an equally long time. However, we cannot rule out that MYC-initiated targeting of the DNA methylation machinery could occur as an infrequent aberrant event during tumor development. Comparison of global methylation profiles between different mouse models of T cell lymphomas would not only help to answer this question but it would also address to what degree the global DNA methylation pattern is dependent on initial oncogenic insult.
###end p 52
###begin p 53
The work described here provides an alternative explanation for the longstanding question of tumor-specific CpG island hypermethylation. We find that tumor-specific signatures of CpG island methylation can only be detected late in the neoplastic process, at a time when the clonal expansion of pretumor cells can be observed, suggesting that specific profiles of CpG island methylation arise from the expansion of rare neoplastic cells. While we cannot rule out the possibility that DNA methylation profiles of late-stage tumor cells may indirectly reflect the selection of cells having a unique expression profile, our observation that inactivation of different tumor suppressor pathways results in distinct aberrant DNA methylation signatures indicates that rare DNA methylation events are selected for during the course of tumor development.
###end p 53
###begin p 54
###xml 244 247 244 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Id4</italic>
###xml 252 257 252 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ptprk</italic>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b022">22</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b035">35</xref>
###xml 794 798 794 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
The function of genes silenced by hypermethylation is expected to provide tumor cells with some selective advantage. Indeed, many of the hypermethylated genes identified by RLGS have functions consistent with a tumor suppressor role, including Id4 and Ptprk [22,35]. The observation that inactivation of different tumor suppressor pathways results in distinct aberrant DNA methylation signatures further supports the notion that rare DNA methylation events are selected for during the course of tumor development. We envision that the function of genes that are no longer selected for hypermethylation in each of the three tumor suppressor cohorts studied here must be somehow related or dependent on the function of the specific tumor suppressor targeted for inactivation. The inactivation of Pten, for example, would thus diminish the selective pressure imposed during neoplastic progression for genes involved in similar or related functions. Comparison among the three tumor suppressor cohorts suggested that this selection is strongly influenced by the specific tumor suppressor inactivated in the tumor cell. Remarkably, the strength of the influence that genetics has on this selection mechanism is illustrated by the ability of unbiased statistical algorithms to faithfully predict the tumor suppressor status in each tumor. We would predict that the nature of the initiating oncogenic insult, in this case MYC, would have an equally important role in determining the CpG methylation profile of the emerging tumor.
###end p 54
###begin p 55
###xml 656 660 656 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b036">36</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b037">37</xref>
###xml 903 905 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b038">38</xref>
###xml 117 122 <span type="species:ncbi:9606">human</span>
###xml 127 132 <span type="species:ncbi:10090">mouse</span>
###xml 835 840 <span type="species:ncbi:9606">human</span>
###xml 1190 1195 <span type="species:ncbi:10090">mouse</span>
It is clear from in vitro experiments and more recent genome-wide sequencing efforts that the transformation of both human and mouse cells to a malignant phenotype requires multiple sequential genetic lesions. In the context of an evolving tumor, it is likely that the initial genetic insult acts as a driving force for the first round of epigenetic alterations and that subsequent genetic alterations as the tumor evolves lead to further epigenetic selection. There is also evidence that epigenetic alterations influence the evolution of genetic lesions. For example, it has been shown, that the hypermethylation and silencing of the mismatch repair gene MLH1 leads to microsatellite instability in colon cancer [36,37]. Similarly, the silencing induced by promoter hypermethylation of the Werner syndrome gene that occurs in several human cancer types, leads to chromosomal instability and apoptosis [38]. Thus, the coevolution of genetic and epigenetic changes during the transformation of a normal cell may be viewed to fuel the diversity of tumor phenotypes. This interpretation is consistent with the heterogeneity of DNA methylation we observe even within a single genetic cohort of mouse lymphomas.
###end p 55
###begin p 56
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b039">39</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b041">41</xref>
###xml 568 572 568 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 638 640 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b019">19</xref>
###xml 694 699 694 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 703 708 703 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 794 796 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b042">42</xref>
###xml 797 799 797 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b044">44</xref>
###xml 480 485 <span type="species:ncbi:9606">human</span>
While the underlying mechanisms for this selection process are unknown, one could speculate that due to the loss of tumor suppressor function, gene-expression profiles are changed. These changes in gene expression may trigger a cascade of epigenetic events including nucleosome repositioning, histone tail modifications, and subsequently DNA methylation [39-41]. There is indeed evidence that a similar mechanism for the specificity of CpG island methylation is also operative in human malignancies. For example, Weisenberger et al. described the tight association of BRAF mutation with a CpG island methylator phenotype in colon cancer [19], and it is known that in breast cancers with either BRCA1 or BRCA2 mutations stable epigenetic changes reflect gene-expression profiles in these cells [42-44]. In conclusion, our findings suggest that genetic events can determine the course in the epigenetic evolution of DNA methylation during tumor development.
###end p 56
###begin title 57
Materials and Methods
###end title 57
###begin title 58
###xml 30 34 <span type="species:ncbi:10090">mice</span>
Generation and maintenance of mice.
###end title 58
###begin p 59
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 9 10 9 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 8 11 8 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 13 21 13 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Teto-Cre</italic>
###xml 27 45 27 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 310 314 309 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 327 331 326 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LoxP</sup>
###xml 323 332 322 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>LoxP</sup>)</italic>
###xml 446 450 445 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFP</sup>
###xml 436 450 435 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rosa26LOXP<sup>EGFP</sup></italic>
###xml 659 703 658 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC, E&#956;SR-tTA;Teto-MYC; E2f2</italic>
###xml 704 705 701 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 703 706 700 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 708 730 705 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC;p53</italic>
###xml 731 732 727 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 730 733 726 729 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 768 777 763 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LoxP/LoxP</sup>
###xml 733 777 729 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, E&#956;SR-tTA;Teto-MYC;Teto-Cre, Pten<sup>LoxP/LoxP</sup></italic>
###xml 821 825 815 819 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFP</sup>
###xml 783 825 778 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXP<sup>EGFP</sup></italic>
###xml 832 850 826 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 928 931 921 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 931 932 924 925 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 934 938 927 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 938 939 931 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 947 951 940 944 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LoxP</sup>
###xml 943 951 936 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>LoxP</sup></italic>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 280 284 <span type="species:ncbi:10090">Mice</span>
###xml 422 426 <span type="species:ncbi:10090">Mice</span>
###xml 550 555 <span type="species:ncbi:10090">mouse</span>
###xml 826 830 <span type="species:ncbi:10090">mice</span>
###xml 851 855 <span type="species:ncbi:10090">mice</span>
###xml 980 984 <span type="species:ncbi:10090">mice</span>
###xml 1009 1014 <span type="species:ncbi:10090">mouse</span>
###xml 1057 1061 <span type="species:ncbi:10090">Mice</span>
###xml 1173 1177 <span type="species:ncbi:10090">mice</span>
The E2f2-/-, Teto-Cre, and EmuSR-tTA;Teto-MYC mice were obtained from Stuart Orkin (Harvard Medical School, Boston, Massachussetts), Andreas Nagy (Samuel Lunenfeld Research Institute, Toronto, Canada) and Dean W. Felsher (Stanford University, Stanford, California), respectively. Mice carrying the conditional Pten allele (PtenLoxP) were a generous gift from Michael Weinstein (The Ohio State University, Columbus, Ohio). Mice carrying Rosa26LOXPEGFP allele (C57BL/6J background) were purchased from The Jackson Laboratory. Genomic DNA isolated from mouse tails was used in PCR-based genotyping. For this study, standard genetic crosses were used to generate EmuSR-tTA;Teto-MYC, EmuSR-tTA;Teto-MYC; E2f2-/-, EmuSR-tTA;Teto-MYC;p53-/-, EmuSR-tTA;Teto-MYC;Teto-Cre, PtenLoxP/LoxP, and EmuSR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXPEGFP mice. EmuSR-tTA;Teto-MYC mice were kept on a clean FVB/NJ genetic background. Tumor studies involving p53-, E2f2- or PtenLoxP alleles were performed with mice backcrossed into FVB/NJ mouse strain for five times (fifth generation). Mice of appropriate genotypes were monitored and harvested at the terminal stage as judged by the overall health of mice. Normal thymi or thymic tumor masses were homogenized to obtain single-cell suspensions from which red cells were removed using hypotonic cell lysis buffer (BD Pharmingen). Aliquots of cells were snap frozen in liquid nitrogen and used for DNA and RNA isolation as described below.
###end p 59
###begin title 60
DNA isolation.
###end title 60
###begin p 61
###xml 50 52 50 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b045">45</xref>
Genomic DNA was isolated as described previously [45]. Briefly, 20-25 ml of preheated lysis buffer (150 mM EDTA pH 8.0, 10mM Tris HCl pH 8.0, and 1% Sarkosyl) was used to dissolve the tissue at 55 degreesC until the solution became homogenous. An equal amount of phenol:chloroform:isoamylalcohol (50:24:1) was used to extract the genomic DNA. Dialysis of the DNA solution was performed in 10 mM Tris HCL pH8.0 buffer overnight, and RNA was subsequently removed by digestion with RNaseA (500 mug/ml). Genomic DNA was precipitated with ethanol, dissolved in TE buffer, and stored at 4 degreesC.
###end p 61
###begin title 62
RLGS.
###end title 62
###begin p 63
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b046">46</xref>
###xml 378 380 365 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 398 400 381 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 455 456 438 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
RLGS was performed according to the published protocol [46]. Briefly, 7 mug of DNA sample was used in each reaction. The ends of the sheared DNA were blocked with the addition of nucleotide analogs (alphaS-dGTP, alphaS-dCTP, ddATP, and ddTTP) using T4 DNA polymerase. DNA was then digested with 20 U of NotI enzyme (Promega) and generated sticky ends were filled in with [alpha-32P]dCTP and [alpha-32P]dGTP. The labeled DNA was then digested with 20 U EcoRV (Promega) and 0.7 mug was run on 0.8% agarose tube gel (first dimension separation) at 230 V for about 20 h. After electrophoresis, the DNA in the agarose gel was digested with 750 U of HinfI restriction enzyme (Promega) and then electrophoresed into 5% polyacrylamide gel (second dimension separation) at 150-180 V for 18-20 h. The gel was dried and autoradiography was performed on an X-ray film in the presence of one Quanta III intensifying screen (DuPont) at -80 degreesC for 3-21 d.
###end p 63
###begin title 64
RLGS gel analysis.
###end title 64
###begin p 65
###xml 1033 1035 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b022">22</xref>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
RLGS profiles obtained from tumors of different genotypes were compared to the profiles obtained from thymocytes of age-matched normal mice. RLGS fragments present in the profiles of normal thymocytes and absent or reduced in intensity in tumor profiles as determined by visual inspection relative to several neighboring unaltered NotI fragments were scored as DNA methylation events. Each RLGS profile was analyzed two times by independent investigators in a blinded fashion and loss events were scored only if the score was concordant between the two analyses. Loss events were scored as DNA methylation events regardless of the degree of intensity loss. RLGS fragments that were changed at least once within a genetic group from the initial analysis were subsequently marked for second round analysis to insure accuracy of obtained data. To avoid scoring polymorphic changes as DNA methylation events, all spots that showed variable intensity between RLGS profiles derived from FVB/NJ, 129SvIMJ, or C57BL/6J strains were removed [22].
###end p 65
###begin title 66
Southern blotting.
###end title 66
###begin p 67
###xml 298 300 293 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 374 376 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b047">47</xref>
A total of 10 mug of genomic DNA isolated from normal thymocytes or thymic tumors was digested with NotI and EcoRV (New England Biolabs). Following electrophoretic separation using 0.8% agarose gels and transfer to GeneScreen nylon membranes (Perkin-Elmer), the digested DNA was probed with [alpha-32P]dCTP radioactively labeled NotI-EcoRV DNA fragment as described before [47].
###end p 67
###begin title 68
Bisulfite genomic sequencing and COBRA.
###end title 68
###begin p 69
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b048">48</xref>
###xml 314 322 314 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-st003">Table S3</xref>
One microgram of genomic DNA from tumors and normal controls was treated with sodium bisulfite according to published protocols [48]. Primers were designed to allow amplification of both methylated and unmethylated DNA. The sequences of primers used for each of the RLGS derived NotI-EcoRV fragments are listed in Table S3. For COBRA, the PCR product was digested using 10 U of restriction enzyme BstUI and separated on 8% polyacrylamide gel. For bisulfite sequencing, the PCR products were subcloned using the TOPO TA-Cloning kit (Invitrogen). Ten clones for each sample were sequenced using ABI big dye chemistry and compared to original genomic DNA sequence using Seqman 6.1 software (DNASTAR).
###end p 69
###begin title 70
FACS.
###end title 70
###begin p 71
###xml 38 42 37 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFP</sup>
###xml 0 42 0 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXP<sup>EGFP</sup></italic>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 358 362 <span type="species:ncbi:10090">mice</span>
###xml 506 511 <span type="species:ncbi:10090">mouse</span>
EmuSR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXPEGFP mice were harvested at age 21, 31, or 42 d and thymocytes isolated from these mice were sorted for EGFP-positive and EGFP-negative cells using high-speed sorting with FACS Aria (Becton Dickinson). DNA and RNA was extracted from sorted cells and analyzed by RLGS and real-time RT-PCR. Lymphomas from terminally sick mice were characterized by using FACS. Briefly, single-cell suspensions prepared from thymic tumor masses were stained with antibodies specific for mouse T cells, B cells, myeloid and erythroid cells including anti-CD4, anti-CD8, anti-CD3, anti-B220, anti-CD11b, and anti-TER119 antibodies (BD Pharmingen). Stained cells were analyzed using FACSCalibur flow cytometer and CellQuest software (Becton Dickinson). All tumors analyzed in this study were T cell lymphomas and were negative for myeloid marker CD11b, B-cell marker B220, and erythroid marker TER119.
###end p 71
###begin title 72
Quantitative real-time RT-PCR.
###end title 72
###begin p 73
###xml 672 677 665 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 866 874 859 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g004">Figure 4</xref>
###xml 964 982 957 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 1064 1082 1056 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 1224 1232 1215 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030167-st002">Table S2</xref>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
Thymi or tumor masses were collected from mice of different ages and homogenized to obtain single cell suspensions that were used for total RNA isolation with TRIzol reagent according to manufacturer's instructions (Life Technologies). Two to 10 mug of total RNA were used to generate cDNA using Superscript III reverse transcriptase (Invitrogen). Real-time RT-PCR was performed using the BioRad iCycler PCR machine. Each PCR reaction contained 2.0 mul of cDNA template, primers at a concentration of 100 nM, and 1x SYBR Green Reaction Mix (BioRad). Reactions were performed in a final volume of 25 mul in triplicate and data were analyzed using the DeltaCt method, where GAPDH served as the internal control. Each PCR generated only the expected amplicon, as shown by the melting-temperature profiles of the final products, gel electrophoresis, and sequencing. For Figure 4E, we chose threshold of 3-fold of reduction if range of fold repression for that gene in EmuSR-tTA;Teto-MYC-derived tumors was less than 20-fold. If the gene was more severely repressed in EmuSR-tTA;Teto-MYC-derived tumors (range exceeded 20-fold), we chose threshold of 5-fold repression. Primer sequences used for expression studies are listed in Table S2.
###end p 73
###begin title 74
Cell culture and retroviral infections.
###end title 74
###begin p 75
###xml 221 224 221 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">61L</sup>
###xml 190 224 190 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pBABE-puro-MYC, pBABE-hygro Ras<sup>61L</sup></italic>
###xml 228 240 228 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pBABE vector</italic>
###xml 607 610 604 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">61L</sup>
###xml 599 610 596 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC/ Ras<sup>61L</sup></italic>
###xml 828 836 825 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g003">Figure 3</xref>
###xml 856 860 853 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC-</italic>
###xml 868 871 865 868 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">61L</sup>
###xml 865 871 862 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ras<sup>61L</sup></italic>
###xml 990 991 987 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 1217 1221 1214 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC-</italic>
###xml 1229 1232 1226 1229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">61L</sup>
###xml 1226 1232 1223 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ras<sup>61L</sup></italic>
###xml 1315 1323 1312 1320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030167-g003">Figure 3</xref>
###xml 109 115 <span type="species:ncbi:9913">bovine</span>
###xml 1127 1132 <span type="species:ncbi:10090">mouse</span>
###xml 1165 1169 <span type="species:ncbi:10090">mice</span>
###xml 1357 1366 <span type="species:ncbi:10090">nude mice</span>
MEFs were isolated from E13.5 embryos using standard methods. All cells were cultured in DMEM with 15% fetal bovine serum. High titer retroviruses were produced by transient transfection of pBABE-puro-MYC, pBABE-hygro Ras61L or pBABE vector plasmids into the Phoenix-Eco packaging cell line using standard methods. MEFs were infected three times at 12-h intervals with Phoenix cell supernatants containing 4 mug/ml of Sequabrene (Sigma). Infected cells were then selected for a total of 5 d in the presence of 2.5 mug/ml of puromycin and 200 mug/ml of hygromycin. At this point, cells infected with MYC/ Ras61L retroviruses showed transformed phenotype while cells infected with control virus retained normal phenotype. A portion of these cells was harvested and used for DNA isolation (C1 culture and C0 culture, respectively; Figure 3A). The rest of the MYC- and Ras61L-transformed primary MEFs was kept either in culture or resuspended in serum-free DMEM medium at a concentration 1 x 107 cells/ml. Cells (100 ul) were injected subcutaneously into the right and left shoulders and hips of each 8-10-wk-old male athymic nude mouse. Tumors that developed in these mice were harvested 18 d after injection along with MYC- and Ras61L-transformed primary MEFs kept in culture (tumors T2 and culture C2, respectively; Figure 3A). Cells and tumors developed in nude mice were used for DNA isolation and RLGS analysis.
###end p 75
###begin title 76
Statistical analysis.
###end title 76
###begin p 77
###xml 51 94 51 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC, E&#956;SR-tTA;Teto-MYC;E2f2</italic>
###xml 95 96 93 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 94 97 92 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 99 121 97 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC;p53</italic>
###xml 122 123 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 121 124 118 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 162 171 158 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LoxP/LoxP</sup>
###xml 130 171 127 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC;Teto-Cre;Pten<sup>LoxP/LoxP</sup></italic>
###xml 248 250 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b049">49</xref>
###xml 304 307 300 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 309 313 305 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 318 322 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 347 365 343 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 427 429 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b049">49</xref>
###xml 505 507 500 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p-</italic>
###xml 1260 1262 1255 1257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b050">50</xref>
###xml 1468 1486 1463 1480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 1517 1540 1511 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC;E2f2</italic>
###xml 1541 1542 1534 1535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 1540 1543 1533 1536 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 1545 1567 1538 1559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC;p53</italic>
###xml 1568 1569 1560 1561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 1567 1570 1559 1562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 1607 1616 1598 1607 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LoxP/LoxP</sup>
###xml 1575 1616 1567 1607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC;Teto-Cre;Pten<sup>LoxP/LoxP</sup></italic>
###xml 1685 1687 1676 1678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b049">49</xref>
###xml 1819 1837 1810 1827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;SR-tTA;Teto-MYC</italic>
###xml 1874 1876 1864 1866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030167-b049">49</xref>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 366 370 <span type="species:ncbi:10090">mice</span>
DNA methylation frequencies in tumors derived from EmuSR-tTA;Teto-MYC, EmuSR-tTA;Teto-MYC;E2f2-/-, EmuSR-tTA;Teto-MYC;p53-/-, and EmuSR-tTA;Teto-MYC;Teto-Cre;PtenLoxP/LoxP mice were compared across using nonparametric Kruskal-Wallis rank sum test [49]. Pair-wise comparisons of tumors deleted for either p53, E2f2, or Pten with those derived from EmuSR-tTA;Teto-MYC mice were done by applying nonparametric Wilcoxon procedure [49] and were corrected for multiple comparisons with Bonferroni correction. A p-value < 0.0167 (0.05/3) was considered to be significant. Survival time data was analyzed the same way as above since there were no censored observations. Under the assumption that all samples within each group have the same frequency of methylation, the heterogeneity of DNA methylation frequencies across samples within each tumor group was assessed by comparing mean methylation frequencies to its variance using a chi-square statistic. Preferential methylation of RLGS fragments within each group was assessed under the null hypothesis of equal methylation frequencies for each fragment, using a goodness-of-fit test based on 10,000 random simulations. Hierarchical cluster analysis of samples was performed by applying phi-correlation coefficient [50] similarity metric with average linkage method, using all RLGS data with at least one methylation event across the respective samples. For each RLGS fragment, proportion of methylation between tumors from EmuSR-tTA;Teto-MYC group and tumors derived from EmuSR-tTA;Teto-MYC;E2f2-/-, EmuSR-tTA;Teto-MYC;p53-/-, or EmuSR-tTA;Teto-MYC;Teto-Cre;PtenLoxP/LoxP groups, respectively, was compared by applying Fisher's exact test [49]. In order to identify RLGS fragments that showed an increase in methylation events compared to overall average methylation in the EmuSR-tTA;Teto-MYC RLGS profiles, exact Binomial test [49] was applied.
###end p 77
###begin title 78
Supporting Information
###end title 78
###begin title 79
Methylation and Expression of RLGS Sequences
###end title 79
###begin p 80
(3.2 MB PPT)
###end p 80
###begin p 81
Click here for additional data file.
###end p 81
###begin title 82
Bisulfite Sequencing of Selected RLGS Fragments
###end title 82
###begin p 83
(852 KB PPT)
###end p 83
###begin p 84
Click here for additional data file.
###end p 84
###begin title 85
Absence of DNA Methylation in Precancerous Thymocytes
###end title 85
###begin p 86
(3.1 MB PPT)
###end p 86
###begin p 87
Click here for additional data file.
###end p 87
###begin title 88
###xml 18 21 18 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
Overexpression of MYC in Precancerous Thymocytes Does Not Lead to Repression of Genes Methylated in Lymphomas
###end title 88
###begin p 89
(485 KB PPT)
###end p 89
###begin p 90
Click here for additional data file.
###end p 90
###begin title 91
COBRA Analysis of Selected RLGS Fragments in Tumors Derived on Different Genotypes
###end title 91
###begin p 92
(3.4 MB PPT)
###end p 92
###begin p 93
Click here for additional data file.
###end p 93
###begin title 94
Specific DNA Methylation Patterns in Genetic Subgroups
###end title 94
###begin p 95
(55 KB PPT)
###end p 95
###begin p 96
Click here for additional data file.
###end p 96
###begin title 97
Characterization of CpG Islands Methylated in Lymphomas
###end title 97
###begin p 98
(127 KB PPT)
###end p 98
###begin p 99
Click here for additional data file.
###end p 99
###begin title 100
Primer Sequences for Real-Time RT-PCR
###end title 100
###begin p 101
(47 KB PPT)
###end p 101
###begin p 102
Click here for additional data file.
###end p 102
###begin title 103
Primer Sequences for COBRA Assays
###end title 103
###begin p 104
(71 KB PPT)
###end p 104
###begin p 105
Click here for additional data file.
###end p 105
###begin title 106
Random Forrest Analysis
###end title 106
###begin p 107
(73 KB XLS)
###end p 107
###begin p 108
Click here for additional data file.
###end p 108
###begin p 109
RO and AR are supported by a T32 CA106196 fellowship in Cancer Genetics. SHW is supported by a fellowship from Susan G. Komen Breast Cancer Foundation. GL is the recipient of The Pew Charitable Trusts Scholar Award and the Leukemia & Lymphoma Society Scholar Award. CP is the recipient the Leukemia & Lymphoma Society Scholar Award.
###end p 109
###begin title 110
Abbreviations
###end title 110
###begin p 111
combined bisulfite restriction analysis
###end p 111
###begin p 112
fluorescent activated cell sorting
###end p 112
###begin p 113
###xml 0 5 <span type="species:ncbi:10090">mouse</span>
mouse embryonic fibroblast
###end p 113
###begin p 114
restriction landmark genomic scanning
###end p 114
###begin p 115
reverse transcriptase PCR 
###end p 115
###begin title 116
References
###end title 116
###begin article-title 117
The Epigenomics of Cancer
###end article-title 117
###begin article-title 118
Cancer-linked DNA hypomethylation and its relationship to hypermethylation
###end article-title 118
###begin article-title 119
The fundamental role of epigenetic events in cancer
###end article-title 119
###begin article-title 120
###xml 35 40 <span type="species:ncbi:9606">human</span>
A gene hypermethylation profile of human cancer
###end article-title 120
###begin article-title 121
The history of cancer epigenetics
###end article-title 121
###begin article-title 122
Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis
###end article-title 122
###begin article-title 123
Methylation matters
###end article-title 123
###begin article-title 124
Predicting aberrant CpG island methylation
###end article-title 124
###begin article-title 125
###xml 26 31 <span type="species:ncbi:9606">human</span>
CpG island methylation in human lymphocytes is highly correlated with DNA sequence, repeats, and predicted DNA structure
###end article-title 125
###begin article-title 126
###xml 50 55 <span type="species:ncbi:9606">human</span>
Computational prediction of methylation status in human genomic sequences
###end article-title 126
###begin article-title 127
Myc represses transcription through recruitment of DNA methyltransferase corepressor
###end article-title 127
###begin article-title 128
Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor
###end article-title 128
###begin article-title 129
Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia
###end article-title 129
###begin article-title 130
Unanswered questions about the role of promoter methylation in carcinogenesis
###end article-title 130
###begin article-title 131
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns
###end article-title 131
###begin article-title 132
CpG island methylator phenotype in cancer
###end article-title 132
###begin article-title 133
Genetics supersedes epigenetics in colon cancer phenotype
###end article-title 133
###begin article-title 134
CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies
###end article-title 134
###begin article-title 135
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer
###end article-title 135
###begin article-title 136
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype
###end article-title 136
###begin article-title 137
###xml 83 88 <span type="species:ncbi:10090">mouse</span>
###xml 99 104 <span type="species:ncbi:9606">human</span>
A NotI-EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies
###end article-title 137
###begin article-title 138
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
###xml 123 128 <span type="species:ncbi:9606">human</span>
Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia
###end article-title 138
###begin article-title 139
Reversible tumorigenesis by MYC in hematopoietic lineages
###end article-title 139
###begin article-title 140
###xml 77 82 <span type="species:ncbi:10090">mouse</span>
Restriction landmark genomic scanning (RLGS-M)-based genome-wide scanning of mouse liver tumors for alterations in DNA methylation status
###end article-title 140
###begin article-title 141
Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci
###end article-title 141
###begin article-title 142
Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets
###end article-title 142
###begin article-title 143
Global methylation profiling of lung cancer identifies novel methylated genes
###end article-title 143
###begin article-title 144
Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates
###end article-title 144
###begin article-title 145
###xml 38 48 <span type="species:ncbi:111938">gatekeeper</span>
Regulation of PTEN function as a PIP3 gatekeeper through membrane interaction
###end article-title 145
###begin article-title 146
Polymorphisms in the p53 pathway
###end article-title 146
###begin article-title 147
T cell-specific loss of Pten leads to defects in central and peripheral tolerance
###end article-title 147
###begin article-title 148
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 65 71 <span type="species:ncbi:10090">murine</span>
Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss
###end article-title 148
###begin article-title 149
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
###end article-title 149
###begin article-title 150
Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas
###end article-title 150
###begin article-title 151
###xml 133 138 <span type="species:ncbi:9606">human</span>
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines
###end article-title 151
###begin article-title 152
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
###end article-title 152
###begin article-title 153
###xml 71 76 <span type="species:ncbi:9606">human</span>
Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer
###end article-title 153
###begin article-title 154
G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis
###end article-title 154
###begin article-title 155
The mechanism of repression of the myeloid-specific c-fms gene by Pax5 during B lineage restriction
###end article-title 155
###begin article-title 156
Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells
###end article-title 156
###begin article-title 157
Gene-expression profiles in hereditary breast cancer
###end article-title 157
###begin article-title 158
Gene expression profiling predicts clinical outcome of breast cancer
###end article-title 158
###begin article-title 159
###xml 39 44 <span type="species:ncbi:9606">human</span>
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis
###end article-title 159
###begin article-title 160
An expanded system of restriction landmark genomic scanning (RLGS Ver. 1.8)
###end article-title 160
###begin article-title 161
Restriction landmark genome scanning
###end article-title 161
###begin article-title 162
Extra-embryonic function of Rb is essential for embryonic development and viability
###end article-title 162
###begin article-title 163
CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia
###end article-title 163
###begin p 164
currency Current address: Department of Medicine, Stanford University, Stanford, California, United States of America
###end p 164
###begin p 165
A previous version of this article appeared as an Early Online Release on August 16, 2007, 2007 (doi:).
###end p 165
###begin p 166
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. RO, SHW, GL, and CP conceived and designed the experiments. RO, SHW, PT, AR, YH, YZW, BR, GL, and CP performed the experiments. RO, SHW, PT, AR, BK, SL RVD, GL, and CP analyzed the data. GW, MW, DF, MO, and CP contributed reagents/materials/analysis tools. RO, GL, and CP wrote the paper.
###end p 166
###begin p 167
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This work was funded by National Institutes of Health grants CA93548 and CA101956 (CP), P30 CA16058 (GL, CP), HD047470, and CA85619 (GL), and a translational award by the Leukemia & Lymphoma Society of America.
###end p 167
###begin p 168
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 168

